alopecia

Posts

Alopecia Treatment Market

Global Stem Cell Alopecia Treatment Market Research Report 2019-2026

Global Stem Cell Alopecia Treatment Market Research Report 2019-2026

The Global Stem Cell Alopecia Treatment Market Research Report Forecast 2019-2026 is a valuable source of insightful data for business strategists. It provides the Stem Cell Alopecia Treatment industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable).

The research analysts provide an elaborate description of the value chain and its distributor analysis. This Stem Cell Alopecia Treatment Market study provides comprehensive data which enhances the understanding, scope and application of this report.

Key Players:

APEX Biologix
Belgravia Center
Kerastem
Riken Research Institute
RepliCel

This report provides Comprehensive analysis of:

Key market segments and sub-segments
Evolving market trends and dynamics
Changing supply and demand scenarios
Quantifying market opportunities through market sizing and market forecasting
Tracking current trends/opportunities/challenges
Competitive insights
Opportunity mapping in terms of technology breakthroughs

Regional Outlook:

North America
Europe
China
Japan
Southeast Asia
India

The research report also records the present market and its growth potentials in the given period of forecast. An exhaustive and professional outlook of the Global Stem Cell Alopecia Treatment Market research study report has been completed by industry professionals and presented in the most particular manner to present only the details that matter the most.

The report puts explicit emphasis on the most dynamic information of the global market, gained with the assistance of industry-best analytical methods.

Reasons for Buying this Report:

This Stem Cell Alopecia Treatment Market report provides pin-point analysis for changing competitive dynamics

It provides a forward-looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Global Stem Cell Alopecia Treatment Market Research Report 2019-2026

Source

Previous Posts

Alopecia Treatment Market

Global Stem Cell Alopecia Treatment Market Research Report 2019-2026

Global Stem Cell Alopecia Treatment Market Research Report 2019-2026

The Global Stem Cell Alopecia Treatment Market Research Report Forecast 2019-2026 is a valuable source of insightful data for business strategists. It provides the Stem Cell Alopecia Treatment industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable).

The research analysts provide an elaborate description of the value chain and its distributor analysis. This Stem Cell Alopecia Treatment Market study provides comprehensive data which enhances the understanding, scope and application of this report.

Key Players:

APEX Biologix
Belgravia Center
Kerastem
Riken Research Institute
RepliCel

This report provides Comprehensive analysis of:

Key market segments and sub-segments
Evolving market trends and dynamics
Changing supply and demand scenarios
Quantifying market opportunities through market sizing and market forecasting
Tracking current trends/opportunities/challenges
Competitive insights
Opportunity mapping in terms of technology breakthroughs

Regional Outlook:

North America
Europe
China
Japan
Southeast Asia
India

The research report also records the present market and its growth potentials in the given period of forecast. An exhaustive and professional outlook of the Global Stem Cell Alopecia Treatment Market research study report has been completed by industry professionals and presented in the most particular manner to present only the details that matter the most.

The report puts explicit emphasis on the most dynamic information of the global market, gained with the assistance of industry-best analytical methods.

Reasons for Buying this Report:

This Stem Cell Alopecia Treatment Market report provides pin-point analysis for changing competitive dynamics

It provides a forward-looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Global Stem Cell Alopecia Treatment Market Research Report 2019-2026

Source

Previous Posts

Study Reveals How Protein Norin Helps Activate Hair Growth

Study Reveals How Protein Norin Helps Activate Hair Growth

Study Reveals How Protein Norin Helps Activate Hair Growth

A study released today in STEM CELLS identifies a possible new way to regrow hair. The research demonstrates how extracellular vesicles (EVs), isolated from stimulated dermal fibroblasts, promote hair growth via their secretion of the protein norrin — and how norrin is a key player in growing hair.

The discovery could lead to numerous therapeutic treatments for alopecia (hair loss), the researchers say.

Alopecia is a problem impacting millions of people that not only affects their psychological well-being, but endangers certain skin functions, too. Currently available treatments, however — including drugs and transplants — have numerous limitations, leaving scientists searching for other solutions.

Dermal papilla cells, found at the root of a hair follicle, are of interest in this regard as they control the growth and regeneration of the follicles. In part, this is achieved through cell-to-cell communication. Some scientists believe this communication occurs via extracellular vesicles (EVs) secreted by the surrounding cutaneous (skin) cells.

While numerous functions have been attributed to EVs in physiology and pathology, few studies have examined their impact on hair follicles. What scientists do know about EVs and hair is that EVs from dermal papilla cells are able to stimulate the proliferation and migration of follicular keratinocytes (the cells responsible for forming tight junctions with the nerves of the skin). One recent study on mice also showed that EVs from bone marrow-derived mesenchymal stem cells or dermal papilla activated hair growth in the animals, but neither the underlying molecular mechanism nor the mediator molecule(s) behind this were identified.

In the study published in STEM CELLS, a research team led by Daniel Aberdam, Ph.D., of INSERM and the Université de Paris, decided to tackle these questions. In particular, they wanted to investigate the role of EVs isolated from stimulated human dermal fibroblasts in activating dermal papilla cells to promote hair growth.

The results of their study show how activated dermal fibroblasts secrete specific EVs (st-EVs) that enhance hair follicle growth ex vivo. They demonstrate that st-EVs stimulate dermal papilla cells to secrete Norrin, which in turn activates follicular keratinocytes. Norrin is known to play a role in Wnt/-catenin signaling, which previous studies have shown to regulate hair growth.

“Remarkably, norrin-specific receptor, called Frizzled4, is absent from follicular keratinocytes. We showed here that dermal fibroblast EVs carry at their surface Frizzled4 to allow Norrin signaling and hair growth,” Dr. Aberdam said. “As such, our study identifies dermal fibroblast EVs as efficient activators of dermal papilla cells, and norrin as a novel player in regulating hair growth in normal and pathological conditions”.

Dr. Jan Nolta, Editor-in-Chief of STEM CELLS, said, “The detailed molecular studies reported by the Aberdam group have uncovered a deeper level of signaling by extracellular vesicles to promote hair growth. The involvement of frizzled4 and norrin in this pathway is highly important for the development of novel therapies.”

Full Image caption: Microvesicles (EVs) are secreted by dermal fibroblasts (DF) (1) to activate norrin secretion by dermal papilla (DP) cells (2). In turn, Norrin activates follicular keratinocytes (fKer) through its Fzd4 receptor provided by dermal fibroblasts EVs (3) to enhance beta-catenin pathway and hair follicle growth (4).

The full article, “Extracellular vesicles from activated dermal fibroblasts stimulate hair follicle growth through dermal papilla-secreted norrin,” can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3043.

About the Journal:

STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press:

Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world’s first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley:

Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company’s website can be accessed at http://www.wiley.com.

Study Reveals How Protein Norin Helps Activate Hair Growth

Source

Previous Posts

JAK inhibitor promotes hair growth

JAK inhibitor promotes hair growth

JAK inhibitor promotes hair growth in both men, women with androgenetic alopecia

Inflammation plays a key role in male and female pattern hair loss, Neal Walker, DO, president and CEO of Aclaris Therapeutics, said in an interview with Healio Dermatology regarding results from a phase 2 open-label clinical trial in subjects with androgenetic alopecia.

“Looking at the aggregate of the data, any way you looked at it was positive. If you look at target area hair count, the physicians’ global assessment or the subjects’ assessment, they all showed nice results,” Walker said.

The premise for this research came from Angela Christiano, PhD, and her lab at Columbia University.

“She discovered that JAK inhibitors seem to work by promoting the entry of the hair follicle back into the growth phase — the anagen phase,” Walker said. “In recent papers, she has published that part of that action is mediated by local inflammation. There are inflammatory cells that promote the hair follicle stem cell via the JAK signaling. It promotes a resting phase, which you might see clinically as hair loss.”

ATI-502 (Aclaris), an investigational topical Janus kinase (JAK) 1/3 inhibitor, was evaluated in adult women and men with androgenetic alopecia (AGA) and applied to the scalp twice daily for 26 weeks.

Twenty-three of 31 subjects completed 6 months of treatment. Twenty subjects, 14 men and 6 women, had evaluable hair counts, and 22 subjects recorded investigator global assessment and subject self-assessment scores.

The mean change from baseline in non-vellus target area hair count (TAHC) at week 26 was the primary endpoint. The TAHC increase was 15.3 hairs/cm2 in female subjects and 5.6 hairs/cm2 in males, according to a press release from Aclaris.

The investigators rated 16 of 22 subjects (73%) as experiencing increased hair growth, and 18 of 22 subjects (82%) rated themselves as experiencing increased hair growth.

“By inhibiting the local inflammation, you remove that [resting phase and hair loss effect], allowing hair follicle stem cell activation, pushing that follicle back into the anagen phase,” Walker said.

The effect in female subjects was particularly strong, according to Walker. A continued linear hair increase was seen up to 6 months, which is not typical in this condition, he said.

Twelve-month results from this trial are expected by the end of the year.

The treatment is nonhormonal, Walker said, and could be used in a variety of options, such as in monotherapy or in combination with existing therapies.

“One thing that surprised me was how robust the female data was,” Walker said. “ Most people who work in hair loss studies look at males first, then go to females. We just decided to do both. I think that was a pleasant surprise.”

As for the next step, Aclaris will initiate a double-blind, randomized controlled phase 2 dose-ranging clinical trial using higher concentrations of ATI-502 in the first half of 2020.

AGA is the most common form of hair loss, which affects approximately 50 million men and 30 million women in the U.S., according to the release.

“We found that inflammation, in fact, does play a key role in male/female pattern hair loss,” Walker said. “When we were in dermatology residency, that wasn’t dogma. There was a fringe number of dermatologists who thought that perhaps there was a role, but I think we’ve definitively shown that inflammation is a part of this process.” – by Abigail Sutton

JAK inhibitor promotes hair growth in both men, women with androgenetic alopecia

Source

Previous Posts

Alopecia Treatment Market 2019

Alopecia Treatment Market – Global Industry Analysis

Alopecia Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

A sedentary lifestyle, unhealthy eating habits, and growing stress levels are increasingly responsible for severe hair loss and damage, also known as alopecia.

Ageing, hormonal imbalance, and increasing prevalence of cancer, arthritis, hypertension, and depression are other factors causing alopecia.

Thus, the alopecia treatment market is anticipated to witness significant growth in the coming years owing to a surge in the prevalence of alopecia. The number of people seeking alopecia treatment is extremely high in developed nations.

However, increased healthcare expenditure has spurred the demand for alopecia treatment in developing nations such as China and India as well.

The alopecia treatment market is segmented on the basis of product, gender, end user, and geography. By product, the market is segmented into shampoos and conditioners, vitamins and supplements, and other (gels, oils, and serums). On the basis of end user, the market is segmented into homecare settings, dermatology clinics, and others.

The report covers exhaustive analysis on the alopecia treatment market segments, including the leading, declining, and fastest growing segments. It comprises the analysis of market dynamics, the market size and forecast, and the trends, threats, and opportunities.

The study also comprises the vendor landscape, degree of competition, threat of new entrants, and the bargaining power of buyers and suppliers.

Overview of the Alopecia Treatment Market

According to the American Hair Loss Association, 95% of the hair loss in men is caused by androgenetic alopecia. The Association also states moreover, the body also states that around 800 thousand people are undergoing some form of treatment for hair loss across the globe.

The rise in the geriatric population and increasing hypertension and depression among the middle-aged population are some of the factors driving the alopecia treatment market. Growing demand for surgical hair transplant is expected to drive the global alopecia treatment market in the coming years.

An increase in the disposable income of the people, technological advancements in hair treatment medical devices, and a growing emphasis on looking good are some of the other factors driving the market. Moreover, the easy accessibility to scalp treatment is also helping the market to grow.

The global alopecia treatment market is expected to be restricted by the high cost of medications. The probable side effects, reactions, and allergies caused by alopecia treatments will further hamper the growth of the market. Decreased libido, high BP, increase in the heart rate, and erectile dysfunction is some of the side effects caused by alopecia treatment, threatening the market’s growth. However, technological advancements and the development of novel therapeutic drugs are expected to bring new opportunities for growth in the market.

On the basis of geography, the global alopecia treatment market is segmented into Europe, Asia Pacific, North America, and the Rest of the World, of which North America is currently the largest segment. North America is also the most significant revenue generator at present, owing to the rise in hair loss among people and the high treatment rates. The high disposable income of the people and the availability of innovative therapeutic solutions are also factors driving the growth of the market in North America.

Companies Mentioned in the Report

The report profiles leading players in the global alopecia treatment market. Important information pertaining to players, such as their recent developments, product picture, specifications, and price, and the challenges faced by them are included. Additionally, the report covers strategies adopted by key players to grow in the alopecia treatment market.

The key vendors include Vitabiotics, Sun Pharma, Merck & Co., Alpecin, Dr. Reddy’s Laboratories, Cipla, Johnson & Johnson, Kirkland Signature, Phyto Ales Group, and Lifes2good.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market

Alopecia Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

 

Source

Previous Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market– Industry Trends and Forecast to 2026

The Global Alopecia Treatment (Hair Loss) Market is expected to rise from its initial estimated value of USD 8.21 billion in 2018 to an estimated value of USD 12.40 billion by 2026 registering a CAGR of 5.3% in the forecast period of 2019-2026. This rise in the market can be attributed to the rising geriatric population along with high demand for surgical hair transplant and changing lifestyle.
Market Definition: Global Alopecia Treatment (Hair Loss) Market

Alopecia areata is a medical condition which is a type of alopecia which attacks the hair follicles causes the breakage or fall of hair leading to complete baldness. The patient suffering from alopecia areata, their scalp becomes patchy, diffused and confluent pattern leading the hair fall initially and later spread over the entire scalp termed as alopecia totalis or entire epidermis.

Alopecia areata is an autoimmune hair loss on the scalp or on the body and commonly it shows in the form of solitary and multiple patches of alopecia.

Market Drivers:

Rising geriatric population along with high demand for surgical hair transplant will boost the market
Changing lifestyle along with increase in stress level among working class population can fuel the growth of the market

Market Restraints:

High cost of alopecia treatment (hair loss) is acting as a major restraint for the market
Side effects/allergic reactions by treatment also acting as a major market restraint.

Segmentation: Global Alopecia Treatment (Hair Loss) Market

By Disease Type
Androgenic Alopecia
Alopecia Areata
Ciatricial Alopecia
Traction Alopecia
Alopecia Totalis
By Drug Type
Minoxidil
Finasteride
Cyclosporine
Others
By Gender
Male
Female
By Route of Administration
Oral
Topical
Injectable
By Distribution Channel
Hospital
Retail Pharmacies
Online Pharmacies
By Geography
North America
US
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Malaysia
Indonesia
Thailand
Philippines
Rest of Asia-Pacific
The Middle East and Africa
South Africa
Egypt
Saudi Arabia
United Arab Emirates
Israel
Rest of the Middle East and Africa

Key Developments in the Market:

In January, 2018, Concert Pharmaceuticals, Inc. announced U.S. FDA granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, a disease which attacks the hair follicles, leading to hair loss.
In May 2018, Histogen, Inc (U.S.) announced that received approval to Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to study its lead product in female diffuse hair loss.
In March 2017, Perrigo Perrigo Company PLC (U.S.) announced the launch of over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Competitive Analysis: Global Alopecia Treatment (Hair Loss) Market

The global alopecia treatment (hair loss) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of alopecia treatment (hair loss) market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.
Key Market Competitors: Global Alopecia Treatment (Hair Loss) Market

Few of the major market competitors currently working in the alopecia treatment (hair loss) market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson and Johnson, Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Perrigo Company PLC. and Daiichi Sankyo, Inc.
Research Methodology: Global Alopecia Treatment (Hair Loss) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:

Current and future of global alopecia treatment (hair loss) market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds the highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

All segmentation provided above in this report is represented at the country level
All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

 

Global Alopecia Treatment Market– Industry Trends and Forecast to 2026

Source

Previous Posts

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting

Interim Data Analysis from 8 mg Twice-Daily Cohort of Investigational CTP-543 Showed Statistically Significant Effect on Primary Endpoint in Patients with Moderate-to-Severe Alopecia Areata

Concert Pharmaceuticals, Inc. today announced that interim results from its Phase 2 clinical trial evaluating its product candidate CTP-543 in patients with moderate-to-severe alopecia areata will be presented in an oral presentation during the late-breaking clinical trials session at the American Academy of Dermatology (AAD) Annual Meeting on March 2, 2019, in Washington, DC.

The interim results from this dose-ranging trial showed that treatment with CTP-543 administered at an 8 mg twice-daily dose for 24 weeks met the primary endpoint with a statistically significant greater hair regrowth responder rate compared to placebo. The primary endpoint measures the proportion of patients who are responders to treatment, defined as a ≥ 50% relative reduction in their overall Severity of Alopecia Tool (SALT) score from baseline.

“Alopecia areata is a chronic autoimmune disease resulting in patchy or complete hair loss that can have a profound effect on patients’ health and well-being and can impact their daily lives. I am happy to see new investigational medicines emerging with promising clinical data, including Janus kinase (JAK) inhibitors such as CTP-543,” said Dr. Brett King, Associate Professor of Dermatology at Yale School of Medicine. “The data for CTP-543 shows that JAK inhibitors have the potential to be an effective treatment option for patients with this challenging disease.”

Patients with moderate-to-severe alopecia areata enrolled in the first two cohorts received 4 mg or 8 mg of CTP-543 twice-daily or placebo twice-daily for 24 weeks. The final cohort evaluating 12 mg of CTP-543 or placebo twice-daily is ongoing. The trial randomized 104 patients in the 4 mg and 8 mg cohorts.

The oral presentation will highlight the interim results for the 8 mg twice-daily dosing cohort of CTP-543, which achieved the Phase 2 trial’s primary endpoint, in patients with moderate-to-severe alopecia areata after 24 weeks of dosing. 47% of patients treated with 8 mg of CTP-543 twice-daily achieved a ≥ 50% relative reduction in their overall SALT, score from baseline, which was a significant improvement compared to 8.6% for placebo (p < 0.001).

The responders in the 8 mg twice-daily dose group were evenly distributed among patients with patchy alopecia areata and the more severe forms, alopecia totalis and alopecia universalis. The percentage of patients achieving the primary endpoint continued to increase up to Week 24, and regrowth of hair did not appear to plateau at Week 24. For the 4 mg cohort, 21% of patients achieved a ≥ 50% relative reduction in their overall SALT score from baseline, however these differences were not significantly different from placebo.

The most common side effects in the interim analysis were headache, upper respiratory tract infection, cough, acne and nausea. No serious adverse events were reported.

“We are very pleased that we were selected to present our initial safety and efficacy data with CTP-543 in patients with moderate to severe alopecia areata to the members of the Academy. We believe the results are highly encouraging and we are excited to share these data with the broader treatment community at the annual meeting,” stated James V. Cassella, Ph.D., Concert’s Chief Development Officer, who will make the oral presentation at AAD. “We look forward to advancing the development of CTP-543, as we continue our efforts to bring a new treatment to patients with this medical disease that currently has no approved medications.”

Details from the oral presentation, entitled “JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2a Trial in Alopecia Areata,” will be posted in the Scientific Presentations section of Concert’s website at the start of the oral presentation at the AAD on Saturday, March 2, 2019 at 1:20 p.m. ET.

The Phase 2 trial is a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata.

The primary outcome measure will utilize the Severity of Alopecia Tool (SALT) after 24 weeks of dosing. Patients were sequentially randomized to receive one of three doses of CTP-543 (4 mg, 8 mg, or 12 mg) or placebo twice-daily.

The final cohort evaluating a 12 mg twice-daily dose of CTP-543 compared to placebo is fully enrolled and topline data for the overall study, including the 12mg cohort, is expected in the third quarter of 2019. Additional information about the trial (NCT03137381) is available on www.clinicaltrials.gov.

About CTP-543
CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib, a drug which inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jakafi® in the United States for the treatment of certain blood disorders. Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543.

About Alopecia Areata
Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life with the majority of patients initially having symptoms by age 40. It is believed to equally affect both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata

Source

Previous Posts

Hairmore Novel Treatment for Traction Alopecia

Hairmore Novel Treatment for Traction Alopecia

Applied Biology to Enter into a License Agreement with Hairmore for its Novel Treatment for Traction Alopecia

APPLIED BIOLOGY’S NOVEL TAAR RECEPTOR AGONIST TO HELP MILLIONS OF CHINESE WOMEN SUFFERING FROM PONYTAIL INDUCED ALOPECIA

Applied Biology, Inc. (“Applied Biology”) announced today it has entered into a license agreement for the Chinese market for its novel TAAR receptor agonist for the treatment of ponytail induced alopecia.

A recent study conduct by Dr. Goren et al. demonstrated, that approximately 79% of women wearing a ponytail hair style four or more times per week for a period of at least ten years are at high risk for developing ponytail induced alopecia (also known as traction alopecia). No treatment exists for this condition.

While cessation of styling the hair in a ponytail avoids the development of this condition, a large majority of Chinese women continue to wear a ponytail hair style; thus, a prophylactic treatment that prevents the development of ponytail induced alopecia is of great clinical importance. Recently, Applied Biology scientists discovered a novel TAAR receptor agonist that when applied to scalp reduces the force exerted by the ponytail on hair follicles; thus, reduces the likelihood of development of ponytail alopecia.

According to Dr. Goren, Chief Medical Officer of Applied Biology: “China is the world’s second largest hair market. We are excited to team with the Hairmore Group, China’s premier hair surgery and treatment centers, to provide this groundbreaking therapy to women.”

ABOUT APPLIED BIOLOGY

Founded in 2003, Applied Biology is a biotechnology company located in Irvine, CA focused on the development of novel innovations for the treatment of hair disorders. Our focused team of scientists and physicians, have made breakthroughs in genetics, molecular biology mechanisms and clinical dermatology that are poised to improve millions of patients’ lives.

ABOUT HAIRMORE

Hairmore Group operating 17 surgical centers and over 100 clinics is the leader in hair surgery and hair treatment in China. With focus on quality of care through innovation, Hairmore is expanding its clinical excellence center throughout China and the world.

Applied Biology to Enter into a License Agreement with Hairmore for its Novel Treatment for Traction Alopecia

 

Source

 

Previous Posts

Concert Pharmaceuticals Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata

Concert Pharmaceuticals Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

Concert Pharmaceuticals, Inc. today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 – 5, 2019 in Washington, D.C.

The details of the presentation are as follows:

  • Title: JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata
  • Date and Time: Saturday, March 2, 2019, 1:00 – 4:00 p.m.
  • Session: S034: Late-Breaking Research: Clinical Trials
  • Room: Ballroom A
  • Abstract Number: 11291

About CTP-543

CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib, a drug which inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jaka

fi® in the United States for the treatment of certain blood disorders. Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543.

About Alopecia Areata

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life with the majority of patients initially having symptoms by age 40.

It is believed to equally affect both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.

For more information please visit www.concertpharma.com

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

 

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

 

Source

 

Previous Posts

Oral JAK3 Inhibitor Granted for Alopecia Areata

Oral JAK3 Inhibitor Granted for Alopecia Areata

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata

Phase II data accepted for late-breaker news session at 2018 EADV Congress

Pfizer Inc today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body.1,2

The Breakthrough Therapy designation for alopecia areata was supported by positive results from a Phase 2 study, which will be presented during the late-breaking news session at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris on September 15, 2018.

Currently, there are no FDA-approved treatments for alopecia areata, which impacts millions of people worldwide and is often associated with profound psychological consequences.1,2

“We are encouraged by this Breakthrough Therapy designation as it underscores the potential of our JAK3 inhibitor to address a critical unmet need,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We are continuing to work closely with the FDA on the development process with the goal of bringing this potential new treatment to patients living with alopecia areata as soon as possible.”

Breakthrough Therapy designation was initiated as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) signed in 2012.

As defined by the FDA, a Breakthrough Therapy is a drug intended to be used alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.

If a drug is designated as a Breakthrough Therapy, the FDA will expedite the development and review of such drug.3

Pfizer is also working with the European Medicines Agency (EMA) on the clinical development program for PF-06651600.

About Alopecia Areata

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body.1,2 People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches.1,2 The mean age of onset is between 25 and 35, but it can also impact children and adolescents and is seen in both sexes and all ethnicities.1,2 More than half of the patients with alopecia areata experience poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety.1

About PF-06651600 and Pfizer’s Kinase Inhibitor Leadership

The JAK pathways are believed to play an important role in inflammatory processes as they are involved in signaling for over 50 cytokines and growth factors, many of which drive immune-mediated conditions.4 JAK inhibition offers the potential for new advanced treatment options for these conditions through unique and targeted selectivity.5

“Pfizer strives to continue moving the JAK science forward with development of multiple JAKis with unique selectivity profiles that are being evaluated in clinical trials. These inhibitors have the potential of meeting significant unmet needs in multiple inflammatory conditions,” said Michael Vincent, Chief Scientific Officer, Pfizer Inflammation & Immunology.

PF-06651600 is an oral small molecule that selectively inhibits Janus kinase (JAK) 3.5 PF-06651600 is also under investigation for the treatment of rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

Pfizer has established a leading kinase research capability with multiple unique kinase inhibitor therapies in development. As a pioneer in JAK science, the Company is continuing to advance several investigational programs for molecules with novel selectivity profiles, which, if approved, could potentially deliver transformative therapies for patients. In addition to PF-06651600, Pfizer has the following kinase inhibitors in trials across multiple indications:

PF-04965842: A selective JAK1 inhibitor in Phase 3 clinical trials for the treatment of atopic dermatitis(AD)6; PF-04965842 received Breakthrough Therapy designation from the FDA for the treatment of patients with moderate-to-severe AD
PF-06700841: A tyrosine kinase 2(TYK2)/JAK1 inhibitor under investigation for the treatment of psoriasis, Crohn’s disease, ulcerative colitis and alopecia areata
PF-06650833: An interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor under investigation for the treatment of rheumatoid arthritis
PF-06826647: A TYK2 inhibitor under investigation for the treatment of psoriasis and inflammatory bowel disease (IBD)

Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer healthcare products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of September 5, 2018. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Oral JAK3 Inhibitor Granted for Alopecia Areata

Source

Hair Loss and Balding in Women

Nolopecia Balding and Prostate Cancer

Balding and Prostate Cancer: Lilac Corp reviews a study and recommends Nolopecia, a natural treatment for hair loss

All natural hair loss supplement sold by Lilac Corp

Lilac Corp reviews a study that tested a possible link between early hair loss and prostate cancer.

Nolopecia, targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth.”

A study showed that men with very early onset balding are more likely to develop aggressive prostate cancer, and at a younger age [1]. Some prostate cancers are more dangerous than others. Prostate cancer and androgenic alopecia, also called male pattern baldness, are both dependent on androgen hormones.

The study surveyed 1,941 men and found that men balding at age 20 years had a 50% higher chance of developing aggressive prostate cancer.

Also, these men were diagnosed with cancer an average of 16 months earlier than non-balding men.

Men balding at age 40 years and older, or non-balding men did not have the increased risk. Research like this is important because it helps to identify groups of men with a higher risk for aggressive cancer.

Men who are at a higher risk can perform regular screening tests for prostate cancer and should be followed up closely with their doctor.

For men (and women), who suffer from hair loss and balding, Lilac Corp recommends the natural treatment Nolopecia. Lilac Corp is the company that invented the highly effective and unique antiviral natural treatments Gene-Eden-VIR and Novirin.

The new treatment, called Nolopecia, targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth.

There are many treatments for hair loss on the market.

However, only Nolopecia targets the latent viruses that cause the increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.

About Lilac Corp:

Lilac Corp specializes in the development of biology-based patent protected natural treatments. Currently, Lilac Corp is selling four products: Gene-Eden-VIR, Novirin, Nolopecia, and Noacnin. Lilac Corp ships its products to more than 100 countries around the world.

What makes Lilac Corp special is that all its products are tested in clinical studies that follow FDA guidelines. To ensure transparency, the results of the clinical studies are published in leading scientific journals. Lilac Corp also offers a 90-day money back guarantee.

Source:
[1] Papa, N., MacInnis, R., English, D., Bolton, D., Davis, I., & Lawrentschuk, N. et al. (2017). Early-onset baldness and the risk of aggressive prostate cancer: findings from a case-control study. Cancer Causes & Control, 29(1), 93-102. doi: 10.1007/s10552-017-0981-0

Source

Improved Minoxidil Formulation Safe, Effective for Androgenetic Alopecia